Summersalt Launches International Shipping
18.8.2021 14:01:00 EEST | Business Wire | Press release
Expanding Summersalt’s footprint globally, today the brand announces plans to introduce international shipping to over 180 countries in over 120 different currencies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210818005211/en/
Summersalt’s 2021 “Everybody is a Summersalt Body” campaign (Photo: Business Wire)
Summersalt will launch globally with shipping to Canada, the United Kingdom, India, Australia, Africa, Asia, Europe, South America and more. International customers will be offered a localized check out experience based on their respective currency, language and payment preferences, as well as guaranteed customs, duties and shipping calculations.
“Launching internationally is a logical next step as we strategically build upon Summersalt’s growth domestically and as demand for the brand accelerates worldwide,” said Lori Coulter, CEO, President and Co-founder of Summersalt. “As a digitally native brand, we are excited to expand our reach into new markets and to offer a seamless online shopping and returns experience to Summersalt’s international community.”
“Our customer is a global citizen who loves to travel and explore, and has been requesting Summersalt via every channel since launch day. We are thrilled to offer Summersalt around the world,” said Reshma Chattaram Chamberlin, Chief Digital Brand Officer and Co-founder of Summersalt.
Summersalt was founded on a mission to bring back the childlike joy of wearing a swimsuit by offering designer-quality swimwear at an affordable price. Summersalt offers not only swimwear, but loungewear, activewear, sweaters, pajamas, intimates and more in sizes 0-24.
International expansion plans come on the heels of Summersalt’s highly celebrated “Everybody is a Summersalt Body” campaign, which featured 24 incredible and diverse women, and was centered around joy and self-expression, aiming to empower women to feel good about themselves.
About Summersalt
Summersalt is a generation-defining apparel brand, providing wardrobe essentials for women who are going places. Summersalt launched in 2017 with swimwear made from recycled materials at a $95 price point — designer quality swimwear without the designer price tag. Since then, we’ve launched additional categories including loungewear, knitwear, sleepwear, intimates and activewear. Summersalt pieces are modern, sophisticated and fun, with an impeccable data-backed fit based on millions of measurements from over 10,000 women. In the few short years since our founding, Summersalt has built a loyal following of customers, influencers and celebrities, while garnering praise from leading fashion media including Vogue, Harper’s Bazaar, ELLE and InStyle. In 2019, Summersalt was included in CNBC’s Upstart 100 list and also named one of Fast Company’s Most Innovative Companies in 2020.
To learn more about Summersalt, visit summersalt.com or follow the brand on Instagram and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210818005211/en/
Contact information
Amanda Jacobs
Email: summersalt@azionepr.com
Phone: 646-490-2945
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom